Download Free Immunodiagnosis And Immunotherapy Of Malignant Tumors Book in PDF and EPUB Free Download. You can read online Immunodiagnosis And Immunotherapy Of Malignant Tumors and write the review.

The concept of immunologic responses against tumors is currently under intense scrutiny throughout the world. The evidence for the existence of tumor-specific transplantation antigens (TSTA) and specific immune reactions to them in experimental animals is overwhelming. The available data concerning human tumors are controversial. The reason for this is partially that antigens detectable on human tumors by in vitro assays have not been biologically characterized. In other words, we do not know if the antigens on human tumors are acting as the targets for immunologically mediated rejection processes in vivo. It was the purpose of this workshop to bring experimental tumor immunologists and clinical oncologists together in order to disclose facts and limits in tumor immunology. Clinicians were to learn how shaky the ground becomes once the experimentalist looks beyond the edge of the mouse cage. Tumor biologists heard the clinicians' urgent cry for controlled randomized trials of immunotherapy which thus reflects clearly that immunotherapy in its present form without knowledge of dose-effect-relationship does not work. Nobody would deny that the problem of human cancer smells of immunology, but since we are just about to taste it the essential ingredient might be different. In other words one might look at present rather at immunological epiphenomena than at mechanisms of tumor immul1lty operating in vivo. This problem was among others a central issue of this workshop.
The convening of the 3rd International Workshop on Monoclonal Antibodies and Breast Cancer had the character of a self-search exercise. After almost a decade of research in the basic and applied aspects of the use of serological means to diagnose and possibly treat breast cancer several milestones have been reached. Among them a clear understanding of immunopathological use and limitations of monoclonal antibodies against breast epithelium, the complete development and clinical use of immunoassays for circulating breast epithelial antigens, the striking advances in the diagnostic use of monoclonal antibodies to estrogen and progesterone receptor proteins and the first communications on proposed immunotherapeutic use of different conjugates of anti-breast antibodies. New areas of investigation have developed in our field, some which are reaching a full blossom while others are still facing obstacles and at times a re-definition of their goals and objectives. These meetings have acted in a way as a clearing house and have permitted their attendees to derive predictions that have helped shape future research and fine-tune objectives. But above all, the re-evaluation of past research at these Workshops and the renewed excitement brought to them by new information has helped generate a momentum and enthusiasm that assures for the future large scientific gains.
Updated to reflect changes in the field since publication of the first edition in 1979. Provides a detailed review of the methodology available for assessing the diagnosis and prognosis of cancer patients including data on the application of tumor marker assays and other immunodiagnostic procedures.
Tumor Immunology and Immunotherapy - Integrated Methods Part B, Volume 636 in the Methods in Enzymology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. Chapters in this update include Quantification methods of Transforming Growth Factor beta (TGF??) activity in the setting of cancer immunotherapy, Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses, Tracking and interrogating tissue-resident and recruited microglia in brain tumors, Metabolomics and lipidomics of the tumor microenvironment, Monitoring abscopal responses to radiation in mice, and much more. Provides an array of authors who are authorities in the field Presents comprehensiveness coverage of the topics Includes a broad level of detail and in-depth coverage
Thoroughly updated to reflect major advances in the field of immuno-oncology, this second edition of Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), remains the definitive resource for information on tumor immunology and cancer immunotherapy treatments. An essential reference for both novice and experienced cancer researchers, oncologists, and related practitioners alike, the book not only guides readers through the fundamental scientific principles of the field all the way to translational and practical clinical applications for treating and managing oncologic disease, but also provides a comprehensive understanding of the regulatory processes that support the safe and effective delivery of immunotherapy to patients with cancer. The expanded and updated second edition now spans 68 chapters, including 12 new chapters, covering major topics and innovations that have shaped the rapid development of immunotherapy and its ascension into the standard of care as first-line treatment for a growing number of disease settings. New to this edition are chapters with deeper insight into our understanding of cancer genomics and determinants of response, immunogenic cell death, cancer and stromal cell-intrinsic pathways of immune resistance, cancer immune exclusion, adoptive cell therapy, metabolomics, tumor mutation burden, immunotherapy in combination with radiation therapy, synthetic biology, and more. Complete with detailed illustrations, tables, and key points for targeted reference, Cancer Immunotherapy Principles and Practice, Second Edition is the most comprehensive and authoritative resource for scientists and clinicians looking to expand their knowledge base of this dynamic field. Key Features: Offers key insights and perspectives on cancer immunology and immunotherapy treatments from renowned experts in the field Covers the basic principles and science behind cancer immunotherapy and tumor immunology Includes treatment strategies for a vast array of available immunotherapy classes and agents, such as cytokine therapies, oncolytic viruses, cancer vaccines, CAR T therapies, and combination immunotherapies Provides essential information on FDA-approved immunotherapies, including clinical management and outcome data related to response rates, risks, and toxicities Discusses special considerations for immunotherapy in the context of specific disease settings, including skin cancers, genitourinary cancers, gastrointestinal cancers, hepatocellular carcinomas, gynecologic malignancies, breast cancers, lung cancers, head and neck cancers, brain tumors, sarcomas, pediatric cancers, and treatments combined with radiation therapy Clarifies the complex regulatory aspects behind the development and approval of immunotherapy drugs
Patients are beginning to benefit from antibody based, cellular and vaccine approaches that are effective against genetically diverse and therapy-resistance cancers. BCG immunotherapy is now being used as a first line treatment for human bladder cancer and the introduction of prophylactic vaccination against Hepatitis B and HPV cancers is starting to show positive results. Following recent FDA approval for a vaccination against prostate cancer, and optimistic results in clinical trials for a vaccine targeting cancer antigens in lung cancer, cancer immunotherapy is now significantly impacting patient clinical management. Tumor Immunology and Immunotherapy provides an up-to-date and comprehensive account of cancer immunity and immunotherapy. It discusses our adaptive and innate immunity to cancer, the mechanisms underpinning our immune response, current approaches to cancer immunotherapy, and how tumour and host responses can circumvent effective anti-cancer immunity. The book examines recent results, publications and current areas of interest including 'immune editing' and the specific issues that are affecting the research and development of vaccines, providing insight into how these problems may be overcome, as viewed by world leaders in the field. Tumor Immunology and Immunotherapy will appeal to clinicians working in oncology and cancer immunotherapy, and research scientists including PhD and masters students, post-doctoral researchers and senior investigators.
The concept of immunologic responses against tumors is currently under intense scrutiny throughout the world. The evidence for the existence of tumor-specific transplantation antigens (TSTA) and specific immune reactions to them in experimental animals is overwhelming. The available data concerning human tumors are controversial. The reason for this is partially that antigens detectable on human tumors by in vitro assays have not been biologically characterized. In other words, we do not know if the antigens on human tumors are acting as the targets for immunologically mediated rejection processes in vivo. It was the purpose of this workshop to bring experimental tumor immunologists and clinical oncologists together in order to disclose facts and limits in tumor immunology. Clinicians were to learn how shaky the ground becomes once the experimentalist looks beyond the edge of the mouse cage. Tumor biologists heard the clinicians' urgent cry for controlled randomized trials of immunotherapy which thus reflects clearly that immunotherapy in its present form without knowledge of dose-effect-relationship does not work. Nobody would deny that the problem of human cancer smells of immunology, but since we are just about to taste it the essential ingredient might be different. In other words one might look at present rather at immunological epiphenomena than at mechanisms of tumor immul1lty operating in vivo. This problem was among others a central issue of this workshop.
“Drs. Butterfield, Kaufman and Marincola on behalf of the SITC have created a comprehensive must-have resource covering the basic and translational science behind approved and investigational immune therapies, and disease-by-disease clinical application of the therapies, written by leaders in the field. The textbook will be highly valuable reading for those just entering the field and for experienced scientists and clinicians looking to expand their knowledge base.” —Mario Sznol, MD, Professor of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut “Given the important and exciting advances in cancer immunotherapy, it is not surprising that there is no dearth of books on the subject. Despite the competition, however, this book is a unique masterpiece and a must-have comprehensive resource for anyone interested in this area and for every medical library.” Score: 100, 5 Stars, Doody’s Medical Reviews Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), is the authoritative reference on cancer immunobiology and the immunotherapy treatments that harness the immune system to combat malignant disease. Featuring five sections and over 50 chapters covering the Basic Principles of Tumor Immunology, Cancer Immunotherapy Targets and Classes, Immune Function in Cancer Patients, Disease-Specific Treatments and Outcomes, and Regulatory Aspects of Cancer Immunotherapy, this book covers all major topics that have shaped the development of immunotherapy and propelled it to its current place at the forefront of cancer treatment innovation. This volume is a comprehensive resource for oncologists and fellows, immunologists, cancer researchers, and related practitioners seeking understanding of the basic science and clinical applications of cancer immunotherapy. As well as presenting the evidence for immune-based cancer treatment, it positions immunotherapy in the context of other available cancer treatments and provides data on response rates, risks, and toxicities across a variety of diseases. Filled with detailed tables, and instructive illustrations, as well as key points for quick reference, Cancer Immunotherapy Principles and Practice simplifies a challenging and dynamic subject. KEY FEATURES Clearly summarizes the basic principles and research supporting cancer immunotherapy clinical translation Contains expert guidance and treatment strategies for all immunotherapy classes and agents, including cell-based therapies, monoclonal antibodies, cytokine therapies, checkpoint inhibitors, oncolytic viruses, adjuvant approaches, and treatment combinations Includes expert perspectives from leading authorities in the field Provides information on all FDA-approved immunotherapies, including clinical management and outcome data Discusses clinical aspects of immunotherapy for individual cancer types, including melanoma and other skin cancers, lung cancers, gynecologic cancers, gastrointestinal cancers, hematologic cancers, genitourinary cancers, head and neck cancers, sarcomas, brain and other CNS cancers, breast cancer, and pediatric malignancies. Explains regulatory aspects behind the development and approval of immunotherapy drugs
Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.